Roche is returning the global development and commercialization rights to the investigational cancer asset camonsertib to Repare Therapeutics, the Cambridge, Mass. and Montreal-based oncology company announced Monday.
Tag Archive for: development agreement
Bristol Myers Squibb returned the rights for interleukin-12 (IL-12) immunotherapy program DF6002 to its original owner, Dragonfly Therapeutics, the companies announced Monday.
On Thursday, Fate Therapeutics announced it terminated a 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen. In response, the next-generation cell therapy company’s stock sank by 54% in pre-market trading Friday.
One year after BridgeBio and its partners won accelerated approval for liver cancer drug Truseltiq (infigratinib), the company is pulling a planned Phase III program after its partner announced plans to permanently discontinue distribution of the drug on Wednesday.
Biogen has terminated the company’s asset purchase agreement with Karyopharm Therapeutics, putting a halt to the development of KPT-350 (BIIB100), which was being tested in Phase I as a treatment for amyotrophic lateral sclerosis (ALS).
